PsA: JAK Inhibition

Tofacitinib Scores in TNF inhibitor Resistant Psoriatic Arthritis

Mease et al has reported in the NEJM the results of a phase 3 trial showing tofacitinib (Tofa) to be significantly more effective than placebo in active psoriatic arthritis (PsA) patients who previously failed to respond to tumor necrosis factor inhibitor (TNFi) therapies.

RA Drug Active in Psoriatic Arthritis

Multiple endpoints improved with tofacitinib

Results with oral drug similar to biologics

At the higher 10mg twice daily dose, Tofacitinib was numerical superior to the 5mg twice daily dose as well as Adalimumab 40mg fortnightly, across Psoriatic Arthritis domains of joint, skin, dactylitis and enthesitis.  All 3 active arms were statistically significantly better than placebo.